Constance T Cirrincione

Constance T Cirrincione

UNVERIFIED PROFILE

Are you Constance T Cirrincione?   Register this Author

Register author
Constance T Cirrincione

Constance T Cirrincione

Publications by authors named "Constance T Cirrincione"

Are you Constance T Cirrincione?   Register this Author

23Publications

793Reads

29Profile Views

Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.

Arch Pathol Lab Med 2018 09 26;142(9):1098-1105. Epub 2018 Apr 26.

From the Departments of Pathology (Drs Cardona, Detweiler, Shealy, and Howell) and Internal Medicine (Drs Sung, Wild, Poleski, Balmadrid, and Sullivan), Duke University Medical Center, Durham, North Carolina; and the Department of Biostatistics (Ms Cirrincione), Duke Cancer Institute, Durham, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5858/arpa.2017-0054-OADOI Listing
September 2018

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

J Clin Oncol 2016 08 2;34(22):2602-9. Epub 2016 May 2.

Maura N. Dickler, Mary Ellen Moynahan, Diana E. Lake, and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; William T. Barry, Dana-Farber Cancer Institute; Eric P. Winer, Dana-Farber/Partners Cancer Care, Boston, MA; Constance T. Cirrincione, Duke University, Durham, NC; Matthew J. Ellis, Baylor College of Medicine; Debasish Tripathy, The University of Texas MD Anderson Cancer Center, Houston, TX; Federico Innocenti and Lisa A. Carey, University of North Carolina at Chapel Hill, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte; Hope S. Rugo, University of California at San Francisco, San Francisco, CA; Olwen Hahn, Alliance for Clinical Trials in Oncology, Chicago, IL; and Bryan P. Schneider, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690PMC
August 2016

Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.

J Clin Oncol 2016 Mar 11;34(7):699-705. Epub 2016 Jan 11.

Stuart M. Lichtman and Maria Theodoulou, Memorial Sloan Kettering Cancer Center, New York, NY; Constance T. Cirrincione, Duke University; Harvey Jay Cohen, Duke University Medical Center, Durham; Gustave Magrinat, Cone Health Cancer Center, Greensboro; Hyman B. Muss, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte, CA; Aminah Jatoi, Mayo Clinic, Rochester, MN; Antonio C. Wolff, The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; and Daniel E. Morganstern, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.6341DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872024PMC
March 2016

Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.

J Clin Oncol 2016 Feb 2;34(6):542-9. Epub 2015 Nov 2.

Lisa A. Carey, David W. Ollila, Carey K. Anders, Katherine A. Hoadley, Michael Iglesia, and Charles M. Perou, University of North Carolina Chapel Hill, Chapel Hill; Constance T. Cirrincione and Brandelyn N. Pitcher, Alliance Statistics and Data Center, Duke University, Durham, NC; Donald A. Berry, Alliance Statistics and Data Center, MD Anderson, Houston, TX; William T. Barry, Alliance Statistics and Data Center, Dana-Farber Cancer Institute; Ian E. Krop and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Lyndsay N. Harris, University Hospitals of Cleveland, Cleveland, OH; Norah Lynn Henry, University of Michigan, Ann Arbor, MI; Douglas J. Weckstein, New Hampshire Hematology-Oncology, Hooksett, NH; Baljit Singh, New York University; Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Maggie Chon U. Cheang, Clinical Trials and Statistics Unit, Institute of Cancer Research, Belmont, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.62.1268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980567PMC
February 2016

Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance).

J Natl Cancer Inst 2015 Sep 25;107(9). Epub 2015 Jun 25.

Dana-Farber Cancer Institute, Boston, MA (JAL, EW); Alliance Statistics and Data Center, Durham, NC (CTC); Mayo Clinic, Rochester, MN (ML, JNI); Hofstra North Shore - LIJ School of Medicine, ProHEALTH Care Associates, Lake Success, NY (MC); Northwestern University Feinberg School of Medicine, Chicago, IL (WG); The Angeles Clinic and Research Institute, Santa Monica, CA (SM); Rhode Island Hospital, Providence, RI (WS); St. Barnabas Medical Center, Livingston, NJ (RM); The Genome Institute, Washington University in St. Louis, St. Louis, MO (EM); Department of Genetics, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC (CMP); Breast Cancer Program, Siteman Cancer Center and Washington University School of Medicine, St. Louis, MO (ME); Memorial Sloan Kettering Cancer Center, New York, NY (CAH); Alliance Statistics and Data Center, MD Anderson Cancer Center, Houston, TX (DB); Alliance Statistics and Data Center, Dana-Farber Cancer Institute, Boston, MA (WTB).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/9/djv179.full.pdf
Web Search
http://dx.doi.org/10.1093/jnci/djv179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651106PMC
September 2015

Impact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance).

Ann Surg 2015 Sep;262(3):434-9; discussion 438-9

*Department of Surgery, Brigham and Women's Hospital, Boston, MA †Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC ‡Department of Medical Oncology Women and Infants Hospital and Alpert Medical School of Brown University, Providence, RI §Alliance Statistics and Data Center, MD Anderson Cancer Center, Houston, TX ¶Department of Medical Oncology, Maine Center for Cancer Medicine, Scarborough, ME ∥Department of Medical Oncology, City of Hope Medical Center, Los Angeles, CA **Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY ††Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and ‡‡Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000001417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710511PMC
September 2015

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

J Clin Oncol 2015 Jan 4;33(1):13-21. Epub 2014 Aug 4.

William M. Sikov, Miriam Hospital and Alpert Medical School of Brown University, Providence, RI; Donald A. Berry, University of Texas MD Anderson Cancer Center, Houston, TX; Charles M. Perou and Lisa A. Carey, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Constance T. Cirrincione, Alliance Statistical Center, Durham; Charles S. Kuzma, Southeast Cancer Control Consortium, Winston-Salem, NC; Baljit Singh, New York University Medical Center; Elisa R. Port, Mount Sinai Medical Center; Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; Sara M. Tolaney, Mehra Golshan, Jennifer R. Bellon, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Timothy J. Pluard, Washington University-St Louis Medical Center, St Louis, MO; George Somlo, City of Hope Comprehensive Cancer Center, Duarte; Deborah Collyar, Patient Advocates in Research, Danville, CA; and Olwen M. Hahn, University of Chicago Medical Center, Chicago, IL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.0572DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268249PMC
January 2015

Reply to V. Amoroso et al.

J Clin Oncol 2015 Jan 15;33(3):291. Epub 2014 Dec 15.

Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.1875DOI Listing
January 2015

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance).

J Clin Oncol 2014 Dec 27;32(35):3959-66. Epub 2014 Oct 27.

Harold J. Burstein, William T. Barry, Sara M. Tolaney, and Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Constance T. Cirrincione, Duke University Alliance Statistics and Data Center; Kimberly L. Blackwell, Duke University Medical Center, Durham, NC; Helen K. Chew, University of California, Davis, Davis, CA; Diana E. Lake and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Cynthia Ma, Washington University School of Medicine, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.7941DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251959PMC
December 2014

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

J Clin Oncol 2014 Aug 16;32(22):2311-7. Epub 2014 Jun 16.

Lawrence N. Shulman, Harold J. Burstein, Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Donald A. Berry, MD Anderson Cancer Center, Houston, TX; Constance T. Cirrincione, Gretchen Kimmick, Duke University Medical Center, Durham; Hyman Muss, University of North Carolina at Chapel Hill, Chapel Hill, NC; Heather P. Becker, University of Chicago, Chicago, IL; Edith A. Perez, Mayo Clinic, Jacksonville, FL; Ruth O'Regan, Emory University, Atlanta, GA; Silvana Martino, The Angeles Clinic and Research Institute, Los Angeles, CA; Charles L. Shapiro, The James Cancer Center, Ohio State University, Columbus, OH; Charles J. Schneider, Christiana Healthcare Services, Wilmington, DE; Larry Norton, Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7142DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484PMC
August 2014